The role of immunotherapy in microsatellites stable metastatic colorectal cancer: state of the art and future perspectives
Open accessThe DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
Colorectal cancer (CRC) is the third leading cause of cancer-related deaths worldwide, despite several advances has been achieved in last decades. Few prognostic and predictive biomarkers guide therapeutic choice in metastatic CRC (mCRC), among which DNA mismatch repair deficiency and/or microsatellite instability (dMMR/MSI) holds a crucial role. Tumors characterized by dMMR/MSI benefit from immune checkpoint inhibitors. However, most of the mCRC patients (around 95%) are microsatellite stable (MSS), thereby intrinsically resistant to immunotherapy. This represents a clear unmet need for more effective treatments in this population of patients. In this review, we aim to analyze immune-resistance mechanisms and therapeutic strategies to overcome them, such as combinations of immunotherapy and chemotherapy, radiotherapy or target therapies specifically in MSS mCRC. We also explored both available and potential biomarkers that may better select MSS mCRC patients for immunotherapy. Lastly, we provide a brief overview on future perspectives in this field, such as the gut microbiome and its potential role as immunomodulator.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clinical studies have investigated the potential of chemotherapy to improve the activity of immunotherapy in MSS mCRC, but no therapeutic benefit has been established for this approach [148].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [148]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21708 · Cited by 17,196
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170 · cited 1×
“In contrast, CMS4 shows an immunosuppressive landscape, mainly characterized by M2 macrophages, Th17 cells, and TGF-b overexpression (78).”
BackgroundOverman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Microsatellite Instability in Colorectal Cancer
Boland, C. R., & Goel, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.064 · Cited by 2,456 · cited 1×
“Unfortunately, only 15% of early stages CRC and 5% of mCRC are dMMR/MSI (3), thus the vast majority of mCRC patients do not benefit from this treatment approach.”
BackgroundFecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J.-M., Morrison, R. M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., et al. (2021) · Science · doi:10.1126/science.abf3363 · Cited by 1,781 · cited 1×
“These data suggest that FMT could represent a method to overcome resistance to ICIs in melanoma (93).”
MethodEncorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491 · cited 1×
“The BEACON trial in 2019 (38) set a new therapeutic paradigm for BRAF mutated mCRC and preclinical data demonstrated that the combination of BRAF inhibitor plus epidermal growth factor receptor (EGFR) inhibitor could induce a transient MSI phenotype.”
BackgroundTakahashi, Y., Kitadai, Y., Bucana, C. D., Cleary, K. R., & Ellis, L. M. (1995) · PubMed · Cited by 1,265
Personalized vaccines for cancer immunotherapy
Sahin, U., & Türeci, Ö. (2018) · Science · doi:10.1126/science.aar7112 · Cited by 1,147 · cited 1×
“Research is also active on developing cancer vaccines, based on cancer-specific neoepitopes bounded by T-cells in order to enhance immunological response (82).”
BackgroundGabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S., & Carbone, D. P. (1998) · Blood · doi:10.1182/blood.v92.11.4150 · Cited by 1,048 · cited 2×
“The anti-angiogenic bevacizumab seems to potentiate dendritic cells’ functions, to facilitate CD8+ lymphocytes infiltration into tumor and to decrease Tregs functions, important studies such as the MODUL trial, cited above, and the BACCI trial (capecitabine in frontiersin.org association with bevacizumab and atezolizu…”
BackgroundLiver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination
Yu, J., Green, M. D., Li, S., Sun, Y., Journey, S. N., Choi, J. E., Rizvi, S. M., Qin, A., Waninger, J. J., Lang, X., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-1131-x · Cited by 1,001 · cited 1×
“These results are consistent with those observed in other advanced tumors (85) and suggest that the l iver micro-environment may show immunosuppressive features (86), with low tumor control by immune checkpoint inhibitors (87).”
ResultThe CORGI Consortium, Palles, C., The WGS500 Consortium, Cazier, J.-B., Howarth, K. M., Domingo, E., Jones, A. M., Broderick, P., Kemp, Z., Spain, S. L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2503 · Cited by 997
Diaz, L. A., Shiu, K.-K., Kim, T.-W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00197-8 · Cited by 945
Fukuoka, S., Hara, H., Takahashi, N., Kojima, T., Kawazoe, A., Asayama, M., Yoshii, T., Kotani, D., Tamura, H., Mikamoto, Y., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03296 · Cited by 890
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Saito, T., Nishikawa, H., Wada, H., Nagano, Y., Sugiyama, D., Atarashi, K., Maeda, Y., Hamaguchi, M., Ohkura, N., Sato, E., et al. (2016) · Nature Medicine · doi:10.1038/nm.4086 · Cited by 871 · cited 1×
“In addition, both intensity and quality of the TME can influence response to immunotherapy (15): a high prevalence of FOXP3 positive regulatory T cells (Treg) or myeloid derived suppressor cells (MDSC) is associated with poor prognosis in several neoplasms, although their role in CRCs is more complex and under further…”
BackgroundThe Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
Emens, L. A., & Middleton, G. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0064 · Cited by 831
Epigenetics of colorectal cancer: biomarker and therapeutic potential
Jung, G., Hernández-Illán, E., Moreira, L., Balaguer, F., & Goel, A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0230-y · Cited by 813
Ebert, P. J. R., Cheung, J., Yang, Y., McNamara, E., Hong, R., Moskalenko, M., Gould, S. E., Maecker, H., Irving, B. A., Kim, J. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.024 · Cited by 713 · cited 1×
“Several preclinical models and different studies have suggested that MEK inhibition can lead to up-regulation of MHC I and increase the infiltration of CD8+ into the tumors (40, 41).”
BackgroundRegulatory T cells in cancer immunotherapy
Nishikawa, H., & Sakaguchi, S. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.12.005 · Cited by 705 · cited 1×
“In addition, both intensity and quality of the TME can influence response to immunotherapy (15): a high prevalence of FOXP3 positive regulatory T cells (Treg) or myeloid derived suppressor cells (MDSC) is associated with poor prognosis in several neoplasms, although their role in CRCs is more complex and under further…”
BackgroundNeoantigen vaccine: an emerging tumor immunotherapy
Peng, M., Mo, Y., Wang, Y., Wu, P., Zhang, Y., Xiong, F., Guo, C., Wu, X., Li, Y., Li, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1055-6 · Cited by 700
Radiotherapy combined with immunotherapy: the dawn of cancer treatment
Zhang, Z., Liu, X., Chen, D., & Yu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01102-y · Cited by 670
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth
Germano, G., Lamba, S., Rospo, G., Barault, L., Magrì, A., Maione, F., Russo, M., Crisafulli, G., Bartolini, A., Lerda, G., et al. (2017) · Nature · doi:10.1038/nature24673 · Cited by 627 · cited 1×
“therefore, increase the mutational burden and trigger immune surveillance (26).”
BackgroundSchrock, A. B., Ouyang, C., Sandhu, J., Sokol, E., Jin, D., Ross, J. S., Miller, V. A., Lim, D., Amanam, I., Chao, J., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz134 · Cited by 617 · cited 1×
“reported a cut-off of 37-41 mut/Mb (68), in the REGONIVO trial the cut-off was 22.”
BackgroundEng, C., Kim, T. W., Bendell, J., Argilés, G., Tebbutt, N. C., Di Bartolomeo, M., Falcone, A., Fakih, M., Kozloff, M., Segal, N. H., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30027-0 · Cited by 577
Loi, S., Dushyanthen, S., Beavis, P. A., Salgado, R., Denkert, C., Savas, P., Combs, S., Rimm, D. L., Giltnane, J. M., Estrada, M. V., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1125 · Cited by 536
Systematic review of case reports on the abscopal effect
Abuodeh, Y., Venkat, P., & Kim, S. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2015.10.001 · Cited by 532
Wang, F., Zhao, Q., Wang, Y.-N., Jin, Y., He, M.-M., Liu, Z.-X., & Xu, R.-H. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.2963 · Cited by 436
Chen, E. X., Jonker, D. J., Loree, J. M., Kennecke, H. F., Berry, S. R., Couture, F., Ahmad, C. E., Goffin, J. R., Kavan, P., Harb, M., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0910 · Cited by 392 · cited 5×
“Frontiers in Oncology 08 trial it was 28 mut/Mb (52).”
BackgroundInfluentialThe prevalence of PIK3CA mutations in gastric and colon cancer
Velho, S., Oliveira, C., Ferreira, A., Ferreira, A. C., Suriano, G., Schwartz, S., Duval, A., Carneiro, F., Machado, J. C., Hamelin, R., et al. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.04.022 · Cited by 341 · cited 1×
“PIK3CA mutations, that can be found in about 13% of CRCs regardless theMMR status (13) and can be secondary to a loss of Phosphatase and tensin homolog (PTEN) (14), are associated with Programmed Death-Ligand 1 (PDL-1) expression and immunosuppressive effect.”
BackgroundGoldberg, M. V., & Drake, C. G. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2010_114 · Cited by 337 · cited 1×
“LAG3 is a surface molecule expressed by immunity cells that plays a role in the regulation of lymphocytes and dendritic cells’ activity (55).”
BackgroundDomingo, E., Freeman-Mills, L., Rayner, E., Glaire, M., Briggs, S., Vermeulen, L., Fessler, E., Medema, J. P., Boot, A., Morreau, H., et al. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30014-0 · Cited by 308
Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy
Goodman, A. M., Sokol, E. S., Frampton, G. M., Lippman, S. M., & Kurzrock, R. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0149 · Cited by 306 · cited 1×
“Therefore, the prevalence of TMB-high could be more significant than expected in the mCRC population (65), implying the necessity of testing it on a large scale (66).”
BackgroundImmunotherapy of colorectal cancer: Challenges for therapeutic efficacy
Ciardiello, D., Vitiello, P. P., Cardone, C., Martini, G., Troiani, T., Martinelli, E., & Ciardiello, F. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.04.003 · Cited by 304
Parikh, A. R., Szabolcs, A., Allen, J. N., Clark, J. W., Wo, J. Y., Raabe, M., Thel, H., Hoyos, D., Mehta, A., Arshad, S., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00269-7 · Cited by 294 · cited 4×
“A recent phase 2 trial [NCT03104439] has evaluated the combination of fractioned radiotherapy (8 Gy in three fractions to a single metastatic lesion) with ipilimumab and nivolumab in 40 patients with MSS metastatic colorectal and pancreatic cancer.”
BackgroundInfluentialFabrizio, D. A., George Jr, T. J., Dunne, R. F., Frampton, G., Sun, J., Gowen, K., Kennedy, M., Greenbowe, J., Schrock, A. B., Hezel, A. F., et al. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.05.06 · Cited by 260
Woolston, A., Khan, K., Spain, G., Barber, L. J., Griffiths, B., Gonzalez-Exposito, R., Hornsteiner, L., Punta, M., Patil, Y., Newey, A., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.013 · Cited by 254 · cited 1×
“Preclinical data showed that anti-EGFR therapy can contribute to activate a tumor-specific adaptive immune response and immunogenic apoptosis, often associated with an increased expression of CTLA-4 and PD-L1, during the development of treatment resistance (51).”
BackgroundEmerging role of PTEN loss in evasion of the immune response to tumours
Vidotto, T., Melo, C. M., Castelli, E., Koti, M., dos Reis, R. B., & Squire, J. A. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0834-6 · Cited by 209 · cited 1×
“PIK3CA mutations, that can be found in about 13% of CRCs regardless theMMR status (13) and can be secondary to a loss of Phosphatase and tensin homolog (PTEN) (14), are associated with Programmed Death-Ligand 1 (PDL-1) expression and immunosuppressive effect.”
BackgroundCombinations of Bevacizumab With Cancer Immunotherapy
Chen, D. S., & Hurwitz, H. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000327 · Cited by 207 · cited 10×
“In addition, both intensity and quality of the TME can influence response to immunotherapy (15): a high prevalence of FOXP3 positive regulatory T cells (Treg) or myeloid derived suppressor cells (MDSC) is associated with poor prognosis in several neoplasms, although their role in CRCs is more complex and under further…”
BackgroundInfluentialRationale and Design of the Targeted Agent and Profiling Utilization Registry Study
Mangat, P. K., Halabi, S., Bruinooge, S. S., Garrett-Mayer, E., Alva, A., Janeway, K. A., Stella, P. J., Voest, E., Yost, K. J., Perlmutter, J., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00122 · Cited by 189 · cited 1×
“The basket trial TAPUR evaluated the efficacy of already available target agents in metastatic solid tumors showing specific somatic genomic variants (69).”
BackgroundNoman, M. Z., Buart, S., Van Pelt, J., Richon, C., Hasmim, M., Leleu, N., Suchorska, W. M., Jalil, A., Lecluse, Y., El Hage, F., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0800854 · Cited by 183
Martinelli, E., Martini, G., Famiglietti, V., Troiani, T., Napolitano, S., Pietrantonio, F., Ciardiello, D., Terminiello, M., Borrelli, C., Vitiello, P. P., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.2915 · Cited by 182
Cause, Epidemiology, and Histology of Polyps and Pathways to Colorectal Cancer
Sullivan, B. A., Noujaim, M. G., & Roper, J. (2022) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2021.12.001 · Cited by 179 · cited 1×
“The majority (85%) of CRC presents a chromosomal instability and are typically MSS (4), while 15% have genetic instability, resulting in high MSI status.”
BackgroundPhase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.
Hellmann, M. D., Kim, T.-W., Lee, C. B., Goh, B.-C., Miller, W. H., Oh, D.-Y., Jamal, R., Chee, C.-E., Chow, L. Q. M., Gainor, J. F., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz113 · Cited by 174 · cited 1×
“They reported a response rate in seven patients (8% of the cohort), of whom six patients had microsatellite stable status (43).”
BackgroundXu, X., Lv, J., Guo, F., Li, J., Jia, Y., Jiang, D., Wang, N., Zhang, C., Kong, L., Liu, Y., et al. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00814 · Cited by 173
Salem, M. E., Bodor, J. N., Puccini, A., Xiu, J., Goldberg, R. M., Grothey, A., Korn, W. M., Shields, A. F., Worrilow, W. M., Kim, E. S., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33115 · Cited by 164 · cited 1×
“However, it is difficult to define when a tumor is TMB-high and when it is low, since several methods of analysis and ways to express the results are available (67).”
BackgroundSelf-citationClinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).
Bendell, J. C., Kim, T. W., Goh, B. C., Wallin, J., Oh, D.-Y., Han, S.-W., Lee, C. B., Hellmann, M. D., Desai, J., Lewin, J. H., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3502 · Cited by 162
Cousin, S., Cantarel, C., Guégan, J., Gomez‐Roca, C., Metges, J., Adenis, A., Pernot, S., Bellera, C. A., Kind, M., Auzanneau, C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3416 · Cited by 160
Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy
Morse, M. A., Höchster, H. S., & Benson, A. B. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0176 · Cited by 140
Morano, F., Raimondi, A., Pagani, F., Lonardi, S., Salvatore, L., Cremolini, C., Murgioni, S., Randon, G., Palermo, F., Antonuzzo, L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02583 · Cited by 134
Fakih, M., Raghav, K. P. S., Chang, D. Z., Larson, T., Cohn, A. L., Huyck, T. K., Cosgrove, D., Fiorillo, J. A., Tam, R., D’Adamo, D. R., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.101917 · Cited by 131
Mettu, N. B., Ou, F.-S., Zemla, T. J., Halfdanarson, T. R., Lenz, H.-J., Breakstone, R. A., Boland, P. M., Crysler, O. V., Wu, C., Nixon, A. B., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.49040 · Cited by 126
Hypoxia and the phenomenon of immune exclusion
Pietrobon, V., & Marincola, F. M. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-020-02667-4 · Cited by 119 · cited 1×
“In addition to the primarily low involvement of the immune system, immunity cells may be selected to limit their efficiency according to the so called “immune exclusion” phenomenon (8).”
BackgroundGarralda, E., Sukari, A., Lakhani, N. J., Patnaik, A., Lou, Y., Im, S.-A., Golan, T., Geva, R., Wermke, M., de Miguel, M., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100639 · Cited by 101
Kim, R. D., Kovari, B. P., Martinez, M., Xie, H., Şahin, İ. H., Mehta, R. J., Strosberg, J., Imanirad, I., Ghayouri, M., Kim, Y., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.03.026 · Cited by 92
Zeng, X., Ward, S. E., Zhou, J., & Cheng, A. S. L. (2021) · Cancers · doi:10.3390/cancers13102418 · Cited by 88
Yoon, H. H., Shi, Q., Heying, E. N., Muranyi, A., Bredno, J., Ough, F., Djalilvand, A., Clements, J., Bowermaster, R., Liu, W.-W., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1984 · Cited by 87
Segal, N. H., Cercek, A., Ku, G., Wu, A. J., Rimner, A., Khalil, D. N., Reidy-Lagunes, D., Cuaron, J., Yang, T. J., Weiser, M. R., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2474 · Cited by 84
Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?
Ghiringhelli, F., & Fumet, J.-D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01816 · Cited by 84 · cited 2×
“In addition, both intensity and quality of the TME can influence response to immunotherapy (15): a high prevalence of FOXP3 positive regulatory T cells (Treg) or myeloid derived suppressor cells (MDSC) is associated with poor prognosis in several neoplasms, although their role in CRCs is more complex and under further…”
BackgroundLi, N., Bai, C., Zhao, L., Sun, Z., Ge, Y., & Li, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.781697 · Cited by 83 · cited 2×
“Indeed, previously studies have demonstrated that some of the gut microbioma’s species can contribute not only to prevent or enhance the risk of CRC, but, furthermore, to modulate efficacy and toxicity of some chemotherapeutic drugs (89, 90).”
BackgroundAntoniotti, C., Borelli, B., Rossini, D., Pietrantonio, F., Morano, F., Salvatore, L., Lonardi, S., Marmorino, F., Tamberi, S., Corallo, S., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07169-6 · Cited by 79
Lu, L., Dong, J., Liu, Y., Qian, Y., Zhang, G., Zhou, W., Zhao, A., Ji, G., & Xu, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.964793 · Cited by 76
Morris, V. K., Parseghian, C. M., Escano, M., Johnson, B., Raghav, K. P. S., Dasari, A., Huey, R., Overman, M. J., Willis, J., Lee, M. S., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.4_suppl.012 · Cited by 76
Fakih, M., Raghav, K. P. S., Chang, D. Z., Bendell, J. C., Larson, T., Cohn, A. L., Huyck, T. K., Cosgrove, D., Fiorillo, J. A., Garbo, L. E., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.3560 · Cited by 72
Huyghe, N. D., Benidovskaya, E., Stevens, P., & den Eynde, M. V. (2022) · Cancers · doi:10.3390/cancers14092241 · Cited by 69
Gomez-Roca, C., Yanez, E., Im, S.-A., Castanon Alvarez, E., Senellart, H., Doherty, M., García-Corbacho, J., Lopez, J. S., Basu, B., Maurice-Dror, C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.3_suppl.94 · Cited by 68
Combined Treatment with Immunotherapy-Based Strategies for MSS Metastatic Colorectal Cancer
Baraibar, I., Mirallas, O., Gonzalez, N. S., Ros, J., Salvà, F., Tabernero, J. M., & Élez, E. (2021) · Cancers · doi:10.3390/cancers13246311 · Cited by 66 · cited 1×
“Nevertheless, more robust preclinical and clinical evidence is needed to assess the predictive role of POLE/POLD1 mutations in MSS mCRC (76).”
BackgroundLenz, H.-J., Parikh, A. R., Spigel, D. R., Cohn, A. L., Yoshino, T., Kochenderfer, M. D., Elez, E., Shao, S. H., Deming, D. A., Holdridge, R. C., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.4_suppl.008 · Cited by 61
Meiri, E., Garrett-Mayer, E., Halabi, S., Mangat, P. K., Shrestha, S., Ahn, E. R., Osayameh, O., Perla, V., & Schilsky, R. L. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.4_suppl.133 · Cited by 52
Patel, M. R., Falchook, G. S., Hamada, K., Makris, L., & Bendell, J. C. (2021) · Cancer Medicine · doi:10.1002/cam4.3630 · Cited by 52
Stein, A., Binder, M., Goekkurt, E., Lorenzen, S., Riera-Knorrenschild, J., Depenbusch, R., Ettrich, T. J., Doerfel, S., Al-Batran, S.-E., Karthaus, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.4_suppl.96 · Cited by 51
Hoff, S., Grünewald, S., Röse, L., & Zopf, D. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx376.060 · Cited by 50 · cited 1×
“In preclinical models, the combination of immunotherapy and tyrosine kinase inhibitors (TKI) in pMMR/MSS CRC cells seems to increase the production of neoantigens and, consequently, to induce immune-mediated cell death (29).”
BackgroundTabernero, J. M., Grothey, A. F., Arnold, D., de Gramont, A., Ducreux, M. P., O'Dwyer, P. J., Tahiri, A., Gilberg, F., Irahara, N., Schmoll, H., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100559 · Cited by 49
Bullock, A. J., Grossman, J. E., Fakih, M., Lenz, H., Gordon, M. S., Margolin, K. A., Wilky, B. A., Mahadevan, D., Trent, J. C., Bockorny, B., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.04.453 · Cited by 48
Barzi, A., Azad, N. S., Yang, Y., Tsao-Wei, D. D., Rehman, R., Fakih, M., Iqbal, S., El-Khoueiry, A. B., Millstein, J., Jayachandran, P., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.4_suppl.015 · Cited by 46 · cited 3×
“3-not reached) months (33) in heavily pre-treated mCRC patients.”
BackgroundInfluentialGarralda, E., Sukari, A. W., Lakhani, N. J., Patnaik, A., Lou, Y., Im, S., Golan, T., Geva, R., Wermke, M., Miguel, M. D., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.3584 · Cited by 45
Lee, M. S., Loehrer, P. J., Imanirad, I., Cohen, S., Ciombor, K. K., Moore, D. T., Carlson, C. A., Sanoff, H. K., & McRee, A. J. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.3_suppl.7 · Cited by 43 · cited 2×
“NCT03442569 (46) nivolumab + ipilimumab + panitumumab II Unresectable or metastatic, II and beyond 100 12 weeks ORR 35%”
BackgroundBrachytherapy attains abscopal effects when combined with immunostimulatory monoclonal antibodies.
Ruiz, M. R., Rodriguez, I., Barbes, B., Mayorga, L., Sánchez-Paulete, A. R., Ponz-Sarvisé, M., Pérez-Gracia, J., & Melero, I. (2017) · Brachytherapy · doi:10.1016/j.brachy.2017.06.012 · Cited by 37 · cited 1×
“Therefore, it was suggested that combining radiotherapy with immunotherapy could represent a good strategy for enhancing the immune system reaction (58).”
BackgroundSchmoll, H., Arnold, D., de Gramont, A., Ducreux, M. P., Grothey, A. F., O'Dwyer, P. J., Cutsem, E. V., Hermann, F., Bosanac, I., Bendahmane, B., et al. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2632-6 · Cited by 34
Natoli, M., Hatje, K., Gulati, P., Junker, F., Herzig, P., Jiang, Z., Davydov, I. I., Germann, M., Trüb, M., Marbach, D., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005548 · Cited by 29
The Microbiome-Immune Axis Therapeutic Effects in Cancer Treatments
Son, Y. M., & Kim, J. (2022) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2208.08002 · Cited by 26 · cited 2×
“In particular, an important role of Bacteroides species in immunostimulatory modulation of CTLA-4 blockade has been identified, while Akkermansia, Faecalibacterium, Clostridiale and Bifidobacterium spp seem to be associated with PD-L1 inhibitors (88).”
BackgroundWen, L., Chen, Z., Ji, X., Fong, W. P., Shao, Q., Ren, C., Cai, Y., Li, B., Yuan, Y., Wang, D., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004487 · Cited by 22 · cited 6×
“This positive result has also been confirmed by the multivariable Cox regression analysis, which showed POLE/POLD1 as an independent biomarker for ICI response.”
BackgroundInfluentialBocobo, A. G., Wang, R., Behr, S. C., Carnevale, J. C., Cinar, P., Collisson, E. A., Fong, L. H., Kidder, W. A., Ko, A. H., Kolli, K. P., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.3_suppl.77 · Cited by 17
Lang, J., Leal, A. D., Marín‐Jiménez, J. A., Hartman, S. J., Shulman, J., Navarro, N. M., Lewis, M. S., Capasso, A., Bagby, S. M., Yacob, B. W., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.877635 · Cited by 17 · cited 7×
“LEAP-005 is a phase 2 study assessing ORR and safety of the combination in previously treated solid tumors, including pMMR/MSS CRC.”
BackgroundInfluentialImplication of gut microbiome in immunotherapy for colorectal cancer
Koustas, E., Trifylli, E.-M., Sarantis, P., Papadopoulos, N., Aloizos, G., Tsagarakis, A., Damaskos, C., Garmpis, N., Garmpi, A., Papavassiliou, A. G., et al. (2022) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v14.i9.1665 · Cited by 16
The effect of CT26 tumor-derived TGF-β on the balance of tumor growth and immunity
Owyang, S. Y., Zhang, M., Walkup, G. A., Chen, G. E., Grasberger, H., Zaatari, M. E., & Kao, J. Y. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.08.024 · Cited by 16
André, T., Overman, M. J., Lonardi, S., Aglietta, M., McDermott, R., Wong, K. Y. M., Morse, M. A., Hendlisz, A., Moss, R. A., Ledeine, J.-M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx393.011 · Cited by 16
Saeed, A., Phadnis, M. A., Park, R., Sun, W., Al-Rajabi, R. M. T., Baranda, J. C., Williamson, S. K., Collins, Z. S., Firth-Braun, J., Saeed, A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.4563 · Cited by 16
Siena, S., Sartore-Bianchi, A., Personeni, N., Pietrantonio, F., Germano, G., Amatu, A., Bonoldi, E., Valtorta, E., Barault, L., Di Nicolantonio, F., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.tps2659 · Cited by 15
Vaccaro, G. M., Rothe, M., Mangat, P. K., Garrett-Mayer, E. S., Hwang, J. J., Alese, O. B., Khalil, M. F., Hameed, M. K., Duvivier, H. L., Cannon, T. L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.4_suppl.107 · Cited by 13
Sarshekeh, A. M., Lam, M. S., Zorrilla, I. R., Holliday, E. B., Das, P., Kee, B. K., Overman, M. J., Parseghian, C. M., Shen, J. P., Tam, A. L., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.4084 · Cited by 12
Targeting Metastatic Colorectal Cancer with Immune Oncological Therapies
Galbraith, N. J., Wood, C. S., & Steele, C. W. (2021) · Cancers · doi:10.3390/cancers13143566 · Cited by 11
Microsatellite Stable Colorectal Liver Metastases—Understanding the Mechanisms of Immune Resistance
Gholami, S., Grothey, A. F., & Lenz, H. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.19025 · Cited by 8 · cited 1×
“These results are consistent with those observed in other advanced tumors (85) and suggest that the l iver micro-environment may show immunosuppressive features (86), with low tumor control by immune checkpoint inhibitors (87).”
ResultIntestinal Microbiota: Novel Personalized Cancer Immunotherapy in Colorectal Cancer
Azimi, M., Shahbaz, S. K., Mansourabadi, A., Khosroshahi, L. M., Pourkalhor, S., Rezakhani, M., & Masoumi, F. (2022) · International Archives of Allergy and Immunology · doi:10.1159/000525695 · Cited by 6
Loree, J. M., Topham, J. T., Kennecke, H. F., Feilotter, H. E., Lee, Y. S., Virk, S., Kopetz, S., Duose, D. Y., Manyam, G. C., Morris, J. S., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.3551 · Cited by 4 · cited 1×
“Unfortunately, among all the combination strategies, some of them have shown unacceptable toxicities or absence of response (durvalumab plus tremelimumab) (80).”
Background
Cited by
Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
“Clinical studies have investigated the potential of chemotherapy to improve the activity of immunotherapy in MSS mCRC, but no therapeutic benefit has been established for this approach [148].”
BackgroundPhase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors
Patel, S. P., Alonso‐Gordoa, T., Banerjee, S. N., Wang, D., Naidoo, J., Standifer, N. E., Palmer, D. C., Cheng, L., Kourtesis, P., Ascierto, M. L., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007340 · Cited by 73
“31 32 In the context of advanced disease after multiple lines of prior therapy, this may be compounded by a lack of immune fitness and a downregulation of effector CD8 + T cells.”
BackgroundLight on life: immunoscore immune-checkpoint, a predictor of immunotherapy response
Hijazi, A., Antoniotti, C., Cremolini, C., & Galon, J. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2243169 · Cited by 49
“Multiple negative immunotherapy trials have been performed in CRC; however, these did not consider the preexisting immunity.(45) Disappointing results from previous trials combining atezolizumab and bevacizumab with a fluoropyrimidine in pre-treated patients make the results of the AtezoTRIBE study significant.”
ResultZhao, N., Lai, C., Wang, Y., Dai, S., & Gu, H. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189096 · Cited by 33
Exploring Predictive and Prognostic Biomarkers in Colorectal Cancer: A Comprehensive Review
Ashouri, K., Wong, A., Mittal, P., Torres‐Gonzalez, L., Lo, J. H., Soni, S., Algaze, S. D., Khoukaz, T., Zhang, W., Yang, Y., et al. (2024) · Cancers · doi:10.3390/cancers16162796 · Cited by 24
“Notably, preclinical models in microsatellite stable (MSS) CRC demonstrate that combined BRAF/EGFR inhibition induces a transient MSI-H/dMMR phenotype [52].”
Background
Metadata
- Authors
- Gandini, A., Puglisi, S., Pirrone, C., Martelli, V., Catalano, F., Nardin, S., Seeber, A., Puccini, A., & Sciallero, S.
- Affiliations
- Ospedale Policlinico San Martino (IT)
- Innsbruck Medical University (AT)
- Corresponding author
- Sciallero, Stefania
- ORCID
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2023-05-03
- Volume
- 13
- Pages
- 1161048-1161048
- ISSN
- 2234-943X (ISSN-L)
- PMC
- PMC10189007
- OpenAlex
- W4367845260
- Cited by
- 42
- References
- 95
- Citations by year
- 2026: 15 · 2025: 17 · 2024: 7 · 2023: 3
- FWCI
- 1.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- metastatic colorectal cancer, microsatellite stable tumors, immunotherapy resistance, immune checkpoint inhibitors, mismatch repair deficiency, microsatellite instability, predictive biomarkers, combination immunotherapy, radiotherapy, targeted therapy, gut microbiota, immunomodulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.